52025-34-0

Basic information

• Product Name: 5-Amino-2-ethoxypyridine
• Synonyms: 5-amino-2-ethoxy-pyridin;6-ethoxy-3-pyridinamin;3-Pyridinamine, 6-ethoxy-;Brn 0116585;Pyridine, 5-amino-2-ethoxy-;2-ETHOXY-5-AMINO PYRIDINE;5-AMINO-2-ETHOXYPYRIDINE;6-ETHOXY-PYRIDIN-3-YLAMINE
• CAS NO: 52025-34-0
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.17
• Product Categories: Amines;blocks;Pyridines;Pyridine
• Mol File: 52025-34-0.mol

Chemical Properties

• Melting Point: 67.5-68.5 °C
• Boiling Point: 269.5 °C at 760 mmHg
• Flash Point: 116.8 °C
• Appearance: /
• Density: 1.101 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.97±0.22(Predicted)
• CAS DataBase Reference: 5-Amino-2-ethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-ethoxypyridine(52025-34-0)
• EPA Substance Registry System: 5-Amino-2-ethoxypyridine(52025-34-0)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36
• Hazardous Substances Data: 52025-34-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-2-ethoxypyridine is used as a key intermediate in the synthesis of primaquine and its analogs. These compounds are essential for the treatment of malaria, a disease caused by Plasmodium parasites. Primaquine and its derivatives have been proven to be effective against both the erythrocytic and exo-erythrocytic stages of the parasite, making them valuable in the fight against malaria.
Additionally, 5-Amino-2-ethoxypyridine may also be utilized in the development of other pharmaceutical compounds due to its unique chemical structure and reactivity. Its potential applications in drug discovery and development make it a valuable research reagent in the pharmaceutical industry.

Upstream product

• 55849-30-4 5-bromo-2-ethoxypyridine 
• 31594-45-3 2-ethoxy-5-nitropyridine 
• 4548-45-2 2-chloro-5-nitropyridine 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 124629-47-6 N,N',N''-tris-(4-ethoxy-phenyl)-guanidine 
• 71720-65-5 sulfanilic acid-(6-ethoxy-[3]pyridylamide) 
• 106853-78-5 6-ethoxy-nicotinonitrile 
• 118420-42-1 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(6-ethoxy-pyridin-3-yl)-acrylamide 
• 162220-83-9 diethyl 2-(6-ethoxy-pyridin-3-ylaminomethylene)malonate 
• 625822-19-7 3-amino-6-ethoxypyridine-2-carbonitrile 
• 1419610-64-2 1-{[(1S,3S)-3-({[6-(ethyloxy)-3-pyridinyl]amino}methyl)-3-hydroxy-1-methylcyclohexaneyl]methyl}-1H-benzimidazole-6-carbonitrile 

Relevant articles and documents

SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES

This invention provides compounds of formula (I) having structure (a) wherein A'' is a diavalent moiety selected from the group (a, b, c) which are useful as inhibitors of protein tyrosine kinase.

ANTICANCER COMPOUNDS

This invention features compounds having formula (I): wherein, R1, R 2,R3, R4, R6, R7, T, X, and Y are as defined herein. This invention also features a method for treating cancer. The method includes administrating to a subject in need thereof a compound of formula (I).

Synthesis and Purification of 6-Ethoxy-4-oxo-1,4-dihydro-[1,5] naphthyridine-3-carboxylic Acid Benzylamide

The synthesis of 6-ethoxy-4-oxo-1,4-dihydro-[1,5]naphthyridine-3- carboxylic acid benzylamide (1) on multikilogram scale is described. The major challenge for the synthesis of this quinolone GABA partial agonist was in the isolation of product of acceptable purity for clinical studies due to the insolubility of this compound. Also described are efforts to circumvent a high-temperature cyclization required for the synthesis of the quinolone ring system.

Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands

The present invention encompasses structures of the Formula or the pharmaceutically acceptable non-toxic salts thereof wherein: x is hydrogen, halogen, (un)substituted alkyl, (un)substituted alkoxy or amino; and Y is (un)substituted alkyl, aryl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.

Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compounds 1a [(E)-N-[4 [4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, 4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.